Biomedical subjects

Chantal Godin

Publications and source records attributed to Chantal Godin.

8 recordsLinked to original sources

PubMed2003

Regulation of the Fanconi anemia group C protein through proteolytic modification.

The function of the Fanconi anemia group C protein (FANCC) is still unknown, though many studies point to a role in damage response signaling. Unlike other known FA proteins, FANCC is mainly localized to the cytoplasm and is thought to act as a messenger of cellular damage rather than an effector of repair. FANCC has been shown to interact with several cytoplasmic and nuclear proteins and to delay the onset of apoptosis through redox regulation of GSTP1. We investigated the fate and function of FANCC during apoptosis. Here we show that FANCC undergoes proteolytic modification by a caspase into a predominant 47-kDa ubiquitinated protein fragment. Lack of proteolytic modification at the putative cleavage site delays apoptosis but does not affect MMC complementation. These results suggest that FANCC function is regulated through proteolytic processing.

Apoptosis↗

PubMed2003

Oligomerization of human presenilin-1 fragments.

To gain insight into presenilin-1 (PS1) structural aspects, we explored the structure-function relationship of its N- and C-terminal (NTF and CTF, respectively) complexes. We demonstrated that both NTF and CTF act as independent but inter-changing binding units capable of binding each other (NTF/CTF) or their homologues (NTF/NTF; CTF/CTF). The Alzheimer's disease-associated PS1 mutations Y115H and M146L do not affect their ability to hetero- and/or homodimerize, thus conserving their basic integrity and function(s). These results suggest that PS1 associates intra-molecularly to form higher order complexes, which may be needed for endoproteolytic cleavage and/or gamma-secretase-associated activity.

Dimerization↗

PubMed2003

Presenilin-1 is indirectly implicated in Notch1 cleavage.

SUMMARY: It has been previously demonstrated that the Notch1 signalling pathway is impaired in presenilin-1 null cells. This observation suggests a role for presenilin-1 in the Notch1 developmental pathway, possibly through physical interaction. Here, we show that presenilin-1 and Notch1 do not interact directly with each other but are associated in the cell. These findings raise the possibility that the gamma-secretase cleavage occurs via a presenilin complex in association with a putative co-factor specific for the molecule that is being cleaved (e.g. Notch1, (beta-amyloid precursor protein, E-cadherin and ErbB-4, all of which are gamma-secretase substrates).

Amyloid Precursor Protein Secretases↗

PubMed2003

Dimerization of presenilin-1 in vivo: suggestion of novel regulatory mechanisms leading to higher order complexes.

A growing body of evidence indicates that presenilins could exist and be active as oligomeric complexes. Using yeast two-hybrid and cell culture analysis, we provide evidence that presenilin-1 (PS1) may self-oligomerize giving rise to specific full-length/full-length homodimers. When expressed in N2A and HEK239T cultured cells, full-length PS1-wt and 5(')myc-PS1-wt form specific homodimers corresponding to twice their molecular weight. The Alzheimer's disease-associated PS1 mutations Y115H, M146L, L392V, deltaE10(PS1(1-289/320-467)), the gamma-secretase dominant negative mutant D257A, and the PS1 polymorphism mutant E318G do not affect their ability to self-oligomerize. Under non-denaturing conditions, endogenous PS1 forms specific homo-oligomers in human cultured cells. The results obtained herein suggest that PS1 associates intramolecularly to form higher order complexes, which may be needed for endoproteolytic cleavage and/or gamma-secretase-associated activity.

Animals↗

PubMed2003

A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.

OBJECTIVE: The goal of this study was to compare the effects of 2 doses of pioglitazone hydrochloride (a thiazolidinedione insulin sensitizer) with placebo on glycated hemoglobin (HbA(1c)), insulin sensitivity, and lipid profiles in patients with type 2 diabetes mellitus who had suboptimal glycemic control and mild dyslipidemia. METHODS: Patients with type 2 diabetes mellitus (HbA(1c) >/=6.5% and </=9.8%) who had not previously received insulin or oral antihyperglycemic medications (OAMs) were randomized to treatment with placebo, pioglitazone 30 mg QD, or pioglitazone 45 mg QD in double-blind fashion for 16 weeks at 41 centers in Canada and Spain. RESULTS: A total of 297 patients were randomized (99 in each group). Overall, 286 (96.3%) were white. Mean (SD) age was 58.4 (10.9) years (range, 24-85 years), mean (SD) body mass index was 31.4 (4.8) kg/m(2), mean (SD) duration of type 2 diabetes mellitus was 20.0 (37.4) months, and 30.6% of patients were receiving medication for dyslipidemia. Treatment with pioglitazone 30 or 45 mg QD for 16 weeks reduced mean HbA(1c) by 0.8% and 0.9% from baseline, respectively (both P < 0.001 vs baseline and placebo). A reduction in HbA(1c) of 0.2% was observed in the placebo group (P = 0.025). In patients with medium (>/=7% to <8%) or high (>/=8% to </=9.8%) baseline HbA(1c), both doses of pioglitazone significantly reduced HbA(1c) (both P < 0.001 vs placebo). Pioglitazone 30 and 45 mg significantly reduced fasting serum insulin versus placebo (P = 0.008 and P = 0.006, respectively) and increased insulin sensitivity by Homeostasis Model Assessment versus placebo (P = 0.039 and P = 0.001, respectively). Relative to placebo, pioglitazone 30 and 45 mg significantly increased high-density lipoprotein cholesterol (HDL-C [P = 0.028 and P < 0.001, respectively]) and lowered the atherogenic index of plasma (P = 0.018 and P < 0.001, respectively). Pioglitazone 45 mg also significantly reduced serum triglycerides, apolipoprotein B, and total cholesterol:HDL-C ratio versus placebo (P = 0.007, P = 0.015, and P = 0.005, respectively). Pioglitazone 30 and 45 mg were associated with a significant reduction in serum alanine aminotransferase relative to placebo (P = 0.036 and P = 0.005, respectively). Pioglitazone appeared to be safe and was well tolerated. CONCLUSIONS: In the present study, pioglitazone 30 and 45 mg produced significant improvements in HbA(1c), insulin sensitivity, and lipid profile in OAM-naive patients with type 2 diabetes mellitus with suboptimal glycemic control and mild dyslipidemia.

Adult↗

PubMed2003

Presenilin-1 interacts directly with the beta-site amyloid protein precursor cleaving enzyme (BACE1).

A neuropathological hallmark of Alzheimer's disease is the presence of amyloid plaques. The major constituent of these plaques, occurring largely in brain areas important for memory and cognition, is the 40-42 amyloid residues (Abeta). Abeta is derived from the amyloid protein precursor after cleavage by the recently identified beta-secretase (BACE1) and the putative gamma-secretase complex containing presenilin 1 (PS1). In an attempt to develop a functional secretase enzymatic assay in yeast we demonstrate a direct binding between BACE1 and PS1. This interaction was confirmed in vivo using coimmunoprecipitation and colocalization studies in human cultured cells. Our results show that PS1 preferably binds immature BACE1, thus possibly acting as a functional regulator of BACE1 maturation and/or activity.

Amyloid Precursor Protein Secretases↗

PubMed2003

[Characterization of three light sources. Study of their efficiency].

Light-emitting sources are currently used to activate the setting reaction of restorative composite resins. It is well known that the polymerization extent of the resins will highly influence their clinical behavior. The monomer-polymer transformation will mostly depend on the chemical nature of the photo-initiators used and on the luminous energy given by the curing device. The aims of this study were to characterize three light curing devices and to compare their efficiency to polymerize a composite resin (SureFil). For that purpose, the emission spectra and the irradiance of a plasma arc (Flipo), a QTH visible light (Elipar Trilight), and a LEDs curing device (Elipar Freelight) were measured. Then, the depth of cure and the Vickers hardness of composite samples were evaluated, for each curing device, as a function of the exposure time. The emission spectra obtained showed the irradiance of the visible light emitted as a function of the wavelength, which was different for each light-curing device. The maximum cured depth (approximately 4 mm) give only a qualitative indication of the extent of the polymerization, as the hardness of the composite samples diminished as a function of the depth. Moreover, it strongly depended on the exposure time. Hence, to obtain a hardness of approximately 100 HV 0.5 at 2 mm depth, the illumination time must be at least of 3 s with the plasma arc Flipo, 10 s with the LEDs Elipar Freelight and 20 s with the QTH Elipar Trilight. In order to efficiently polymerize a composite resin, the emission spectra of the luminous source shall correspond with the absorption spectra of the photo-initiators. The present study showed that the LEDs Elipar Freelight is the most efficient curing device when the camphorquinone is used, as 92% of the emitted energy will be absorbed by the initiator. However, the power of this source is relatively low, hence higher exposure time shall be used.

Composite Resins↗

PubMed2002

Bonding to dentin achieved by general practitioners.

The objectives of this study were (1) to investigate the effect of operator variability on the shear bond strength of adhesives to dentin and (2) to determine the effectiveness of education on bonding performance for different types of adhesives. Thirty general practitioners were recruited for a CE course by a regional mailing. They used bovine dentin as a substrate for bonding the adhesive system they routinely used in practice and two other materials (no previous experience). Each adhesive OptiBond FL, ScotchBond Multipurpose Plus, ScotchBond 1 and Clearfil SE was applied according to manufacturer's instructions and immediately tested using a shear bond strength test. Shear bond strengths between adhesives and dentin were compared before and after a 90 min lecture on bonding principles and materials. For dentists with and without previous experience with a material, there were no statistically significant differences seen before and after the lecture (paired t-tests, p < or = 0.05). However, in every case, the bond strengths after the lecture were higher than those before (range of improvement from 15 to 150%). For dentists with routine experience with a particular material, all materials were statistically equivalent after the lecture, although the OptiBond FL was the highest. For dentists who had no previous experience with a material, the ScotchBond 1 had lower bond strengths than the other materials after the lecture. There was a large range in the ability of dentists to manipulate adhesive systems correctly. However, if a dentist has sufficient experience and receives sufficient education, any of these materials can give reasonable results.

Analysis of Variance↗